NCR1 and acute lymphoblastic leukemia: We next assessed the antileukemia efficacy of resting NK cells from healthy donors against the two BCP-ALL cell lines in the presence of different concentration of NKp46-NKCEs or NKp30-NKCEs, targeting either CD19 or CD20 (Fig. 1B).